SEARCH

SEARCH BY CITATION

References

  • 1
    Lindsay R, Hart DM, Aitken JM, MacDonald ED, Anderson JB, Clarke AC 1976 Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1: 10381041.
  • 2
    Lindsay R, Hart DM, Clark DM 1984 The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63: 759763.
  • 3
    Gordon GS, Picchi J, Roof BS 1973 Antifracture efficacy of long-term oestrogens for osteoporosis. Trans Assoc Am Physicians 86: 326331.
  • 4
    Hutchinson TA, Polansky SM, Feinstein AP 1979 Postmenopausal oestrogens protect against fractures of hip and distal radius. Lancet 2: 706709.
  • 5
    Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S 1998 Hormone replacement therapy and risk of hip fracture: Population based case-control study. The Swedish Hip Fracture Study Group. BMJ 316: 18581863.
  • 6
    Blank RD, Bockman RS 1999 A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom 2: 435452.
  • 7
    Castelo-Branco C, Figueras F, Sanjuan A, Vicente JJ, Martinez de Osaba MJ, Pons F, Balasch J, Vanrell JA 1999 Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: Benefits to bone and analysis of factors associated with discontinuation. Menopause 6: 307311.
  • 8
    Pilon D, Castilloux AM, LeLorier J 2001 Estrogen replacement therapy: Determinants of persistence with treatment. Obstet Gynecol 97: 97100.
  • 9
    Ling X, Lu A, Zhao X, Chen X, Cummings SR 1996 Very low rates of hip fracture in Beijing, People's Republic of China: The Beijing Osteoporosis Project. Am J Epidemiol 144: 901907.
  • 10
    Fukui Y, Miura A, Nara Y, Uesugi T, Yamori H, Yamori Y 2000 Relationship between urinary isoflavones and bone metabolism in postmenopausal Japanese women. J Nutr 130: 686S.
  • 11
    Mei J, Yeung SSC, Kung AWC 2001 High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 86: 52175221.
  • 12
    Somekawa Y, Chiguchi M, Ishibashi T, Aso T 2001 Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 97: 109115.
  • 13
    Mackova Z, Koblovska R, Lapcik O 2006 Distribution of isoflavonoids in non-leguminous taxa - an update. Phytochemistry 67: 849855.
  • 14
    Qin L, Zhang G, Shi Y, Lee KM, Leung PC 2005 Prevention and treatment of osteoporosis with traditional herbal medicine. DengHW, LiuYZ, GuoCY, ChenD (eds.) Current Topics of Osteoporosis. World Scientific Publisher, Singapore, 513531.
  • 15
    Zhang G, Qin L, Hung WY, Shi YY, Leung PC, Yeung HY, Leung KS 2006 Flavonoids derived from herbal Epimedium Brevicornum Maxim. prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. Bone 38: 818825.
  • 16
    Li J, Yu S, Li T, Pang S 2002 In vitro study of the effects of Epimedium on osteoclastic bone resorption in various oral mineralized tissues. Zhonghua Kou Qiang Yi Xue Za Zhi. 37: 391394.
  • 17
    Meng FH, Li YB, Xiong ZL, Jiang ZM, Li FM 2005 Osteoblastic proliferative activity of Epimedium brevicornum Maxim. Phytomedicine 12: 189193.
  • 18
    Wang HF, Zhu GY, Wen SF, Wang LH, Wang WH 2001 Studies on establishment and lifestyle determinants of peak bone density in females of Shanghai urban area. Chin J Osteoporosis 7: 305309.
  • 19
    Lee WT, Cheung CS, Tse YK, Guo X, Qin L, Ho SC, Lau J, Cheng JC 2005 Generalized low bone mass of girls with adolescent idiopathic scoliosis is related to inadequate calcium intake and weight bearing physical activity in peripubertal period. Osteoporos Int 16: 10241035.
  • 20
    Qin L, Zhang G, Hung WY, Shi Y, Leung KS, Yeung HY, Leung KS 2005 Phytoestrogen-rich herb formula ‘XLGB’ prevents OVX-induced deterioration of musculoskeletal tissues at hip in old rats. J Bone Miner Metab 23: 5561.
  • 21
    Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG 1991 Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 164: 4752.
  • 22
    Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D 1998 Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 280: 15101517.
  • 23
    Chinese Osteoporosis Foundation 2006 General Guidelines for R&D of Traditional Chinese Medicine and its Preclinical Evaluation and Clinical Trails in Prevention and Treatment of Osteoporosis and Fragility Fractures. People's Medical Publishing House, Beijing, China.
  • 24
    Kimmel DB, Recker RR, Gallagher JC, Vaswani AS, Aloia JF 1990 A comparison of iliac bone histomorphometric data in postmenopausal osteoporotic and normal subjects. Bone Miner 11: 317325.
  • 25
    Setchell KD, Lydeking-Olsen E 2003 Dietary phytoestrogens and their effect on bone: Evidence from in vitro and in vivo, human observational and dietary intervention studies. Am J Clin Nutr 78(3 Suppl): 593S609S.
  • 26
    Messina M, Ho S, Alekel DL 2004 Skeletal benefits of soy isoflavones: A review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care 7: 649658.
  • 27
    Williamson G, Manach C 2005 Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81(1 Suppl): 243S255S.
  • 28
    Usui T 2006 Pharmaceutical prospects of phytoestrogens. Endocr J 53: 720.
  • 29
    Cooper C 1990 Bone mass throughout life: Bone growth and involution. FrancisRM, DickWC (eds.) Osteoporosis: Pathogenesis and Management. Kluwer Academic Publishers, Dordrecht, Netherlands, 126.
  • 30
    Reeve J 1996 Clinical assessment of the physical properties of bone. CompstonJE (ed.) Osteoporosis: New Perspectives on Causes, Prevention and Treatment. Royal College of Physicians of London, London, UK, 4153.
  • 31
    Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA 2004 The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 79: 326333.
  • 32
    Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T 2004 Soymilk or progesterone for prevention of bone loss: A 2 year randomized, placebo-controlled trial. Eur J Nutr 43: 246257.
  • 33
    Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F 2002 Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study. J Bone Miner Res 17: 19041912.
  • 34
    Chen YM, Ho SC, Lam SS, Ho SS, Woo JL 2004 Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: A double-blind, randomized, controlled trial. Menopause 11: 246254.
  • 35
    Huang HY, Yang HP, Yang HT, Yang TC, Shieh MJ, Huang SY 2006 One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem 17: 509517.
  • 36
    Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Uchiyama S, Yamada K, Ishimi Y 2006 Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: A 1-year randomized placebo-controlled trial. J Bone Miner Res 21: 780789.
  • 37
    Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT 2004 Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial. JAMA 292: 6574.
  • 38
    Scheiber M, Liu J, Subbiah M, Rebar R, Setchell KDR 2001 Dietary soy supplementation reduces LDL oxidation and bone turnover in healthy post-menopausal women. Menopause 8: 384392.
  • 39
    Arjmandi BH, Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME 2001 Soy protein with its isoflavones improves bone markers in middle-aged and elderly women. FASEB J 15: A728.
  • 40
    Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T 2000 Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72: 844852.
  • 41
    Xiao Q, Chen A, Guo F 2005 Effects of Icariin on expression of OPN mRNA and type I collagen in rat osteoblasts in vitro. J Huazhong Univ Sci Technolog Med Sci. 25: 690692.
  • 42
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175179.
  • 43
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 44
    Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 1436314367.
  • 45
    Chen KM, Ge BF, Ma HP, Liu XY, Bai MH, Wang Y 2005 Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie 60: 939942.
  • 46
    Sugimoto E, Yamaguchi M 2000 Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. Int J Mol Med 5: 515520.
  • 47
    Sugimoto E, Yamaguchi M 2000 Stimulatory effect of daidzein in osteoblastic MC3T3-E1 cells. Biochem Pharmacol 59: 471475.
  • 48
    Yamaguchi M, Sugimoto E 2000 Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T3-E1 cells: Activation of aminoacyl-t-RNA synthetase. Mol Cell Biochem 214: 97102.
  • 49
    Blair HC, Jordan SE, Peterson TG, Barnes S 1996 Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 61: 629637.
  • 50
    Williams JP, Jordan SE, Barnes S, Blair HC 1998 Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. Am J Clin Nutr 68(suppl): 1369S1374S.
  • 51
    Gao YH, Yamaguchi M 1999 Suppressive effects of genistein on rat bone osteoclasts: Apoptosis is induced through Ca2+ signaling. Biol Pharm Bull 22: 805809.
  • 52
    Gao YH, Yamaguchi M 2000 Suppressive effect of genistein on rat bone osteoclasts: Involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med 5: 261267.
  • 53
    Okamoto F, Okabe K, Kajiya H 2001 Genistein, a soybean isoflavone, inhibits inward rectifier K+ channels in rat osteoclasts. Jpn J Physiol 51: 501509.
  • 54
    Viereck V, Grundker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC 2002 Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J Cell Biochem 84: 725735.
  • 55
    Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA 2005 Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26: 465478.
  • 56
    Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson J-Å 2004 Estrogen receptor β inhibits 17-β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 15661571.
  • 57
    Ye HY, Liu J, Lou YJ 2005 Preparation of two derivatives from icariin and investigation of their estrogen-like effects. Zhejiang Da Xue Xue Bao Yi Xue Ban 34: 131136.
  • 58
    Totta P, Acconcia F, Virgili F, Cassidy A, Weinberg PD, Rimbach G, Marino M 2005 Daidzein-sulfate metabolites affect transcriptional and antiproliferative activities of estrogen receptor-beta in cultured human cancer cells. J Nutr 135: 26872693.
  • 59
    Cappelletti V, Miodini P, Di Fronzo G, Daidone MG 2006 Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. Int J Oncol 28: 11851191.
  • 60
    Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K 2003 Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88: 46554658.
  • 61
    Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321333.